P2Y12抑制剂对非重症COVID-19住院患者无器官支持生存的影响:一项随机临床试验
这项开放标签、贝叶斯自适应随机临床试验在巴西、意大利、西班牙和美国的60家医院纳入562例非重症COVID-19住院患者,比较治疗剂量肝素联合P2Y12抑制剂与单用治疗剂量肝素。结果显示,联合P2Y12抑制剂并未增加21天内无器官支持天数的改善几率(调整OR 0.83,95%可信区间0.55-1.25),预设无效性标准达到后停止入组。
要点
- 在非重症COVID-19住院患者中,治疗剂量肝素加用P2Y12抑制剂未改善21天内无器官支持天数。
- P2Y12抑制剂组大出血发生6例(2.0%),常规治疗组2例(0.7%),调整OR 3.31(95%CI 0.64-17.2;P=0.15)。
- 因达到预设无效性标准,非重症患者入组提前终止。
核心结论
- 在非重症COVID-19住院患者中,与单用治疗剂量肝素相比,加用P2Y12抑制剂并未增加21天内无器官支持天数的改善几率。
研究设计与样本
- 开放标签、贝叶斯自适应随机临床试验,2021年2月至2021年6月在巴西、意大利、西班牙和美国的60家医院进行,纳入562例非重症COVID-19住院患者。
- 患者按1:1随机分配至治疗剂量肝素联合P2Y12抑制剂组(n=293)或单用治疗剂量肝素(常规治疗)组(n=269),治疗14天或至出院(以较早者为准)。
- P2Y12抑制剂首选替格瑞洛;P2Y12抑制剂组中63%使用替格瑞洛,37%使用氯吡格雷。
- 最终90天随访日期为2021年9月15日;全部562例随机患者完成试验,87%在研究中第1天结束时接受了治疗剂量肝素。
主要发现
- P2Y12抑制剂组无器官支持天数中位数为21天(IQR 20-21天),常规治疗组为21天(IQR 21-21天),调整OR 0.83(95%可信区间0.55-1.25)。
- 无效性定义为OR<1.2,其后验概率为96%。
- P2Y12抑制剂组大出血发生6例(2.0%),常规治疗组2例(0.7%),调整OR 3.31(95%CI 0.64-17.2;P=0.15)。
- 达到预设无效性标准后,非重症患者入组被终止。
关键数值与推荐
- 主要复合结局为无器官支持天数,采用有序量表评估,合并院内死亡(赋值为-1)和存活出院者至指数住院第21天无呼吸或心血管器官支持的天数(范围-1至21天,分数越高表示器官支持越少、结局越好)。
- 主要安全结局为28天内大出血,采用国际血栓与止血学会定义。
局限性
- 非重症患者入组在达到预设无效性标准后终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19. OBJECTIVE: To evaluate the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non-critically ill patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS: An open-label, bayesian, adaptive randomized clinical trial including 562 non-critically ill patients hospitalized for COVID-19 was conducted between February 2021 and June 2021 at 60 hospitals in Brazil, Italy, Spain, and the US. The date of final 90-day follow-up was September 15, 2021. INTERVENTIONS: Patients were randomized to a therapeutic dose of heparin plus a P2Y12 inhibitor (n = 293) or a therapeutic dose of heparin only (usual care) (n = 269) in a 1:1 ratio for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor. MAIN OUTCOMES AND MEASURES: The composite primary outcome was organ support-free days evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and, for those who survived to hospital discharge, the number of days free of respiratory or cardiovascular organ support up to day 21 of the index hospitalization (range, -1 to 21 days; higher scores indicate less organ support and better outcomes). The primary safety outcome was major bleeding by 28 days as defined by the International Society on Thrombosis and Hemostasis. RESULTS: Enrollment of non-critically ill patients was discontinued when the prespecified criterion for futility was met. All 562 patients who were randomized (mean age, 52.7 [SD, 13.5] years; 41.5% women) completed the trial and 87% received a therapeutic dose of heparin by the end of study day 1. In the P2Y12 inhibitor group, ticagrelor was used in 63% of patients and clopidogrel in 37%. The median number of organ support-free days was 21 days (IQR, 20-21 days) among patients in the P2Y12 inhibitor group and was 21 days (IQR, 21-21 days) in the usual care group (adjusted odds ratio, 0.83 [95% credible interval, 0.55-1.25]; posterior probability of futility [defined as an odds ratio <1.2], 96%). Major bleeding occurred in 6 patients (2.0%) in the P2Y12 inhibitor group and in 2 patients (0.7%) in the usual care group (adjusted odds ratio, 3.31 [95% CI, 0.64-17.2]; P = .15). CONCLUSIONS AND RELEVANCE: Among non-critically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor in addition to a therapeutic dose of heparin, compared with a therapeutic dose of heparin only, did not result in an increased odds of improvement in organ support-free days within 21 days during hospitalization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04505774.
引用
- Berger JS, Kornblith LZ, Gong MN, et al. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 35040887. doi:10.1001/jama.2021.23605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。